Status:

COMPLETED

Evaluating the Efficacy of PAP Therapy for Treating OSA in the Home Environment

Lead Sponsor:

ResMed

Conditions:

Obstructive Sleep Apnea (OSA)

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This study will take between 4-6 months (with first patient first visit to last patient last visit expected to span 3-4 months across all study sites). Each participant will use the investigational PA...

Detailed Description

A new PAP device has been developed by ResMed which includes an improved humidification system, a new user interface and optimized workflows. This study will assess the efficacy and usability of the n...

Eligibility Criteria

Inclusion

  • Patients willing to give written informed consent
  • Patients who can read and comprehend English
  • Patients who ≥ 18 years of age
  • Patients being established on PAP therapy for the treatment of OSA for ≥ 6 months
  • Patients currently using AirSense10 (as their primary device)
  • Patients currently using an appropriate mask system (AirFit F20, AirFit P10, AirFit N20, AirFit N30i, AirFit F30i or AirFit P30i)
  • Patients who can trial the investigational device for up to 7 nights
  • Patients who have been compliant to therapy (average of ≥4 hours of usage) for the previous 7 nights of use\* \*the most recent consecutive 7 nights within the last 30 days

Exclusion

  • Patients using Bilevel flow generators
  • Patients who are or may be pregnant
  • Patients with a preexisting lung disease/ condition that would predispose them to pneumothorax (for example: COPD, lung cancer; fibrosis of the lungs; recent (\< 2years) case of pneumonia or lung infection; lung injury.
  • Patients believed to be unsuitable for inclusion by the researcher
  • Patients who or whose bed partner has implantable metallic implants in the head, neck and chest region affected by magnetic fields (Non-ferrous implants may be acceptable)
  • Patients using supplemental oxygen

Key Trial Info

Start Date :

August 12 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 5 2021

Estimated Enrollment :

108 Patients enrolled

Trial Details

Trial ID

NCT04744038

Start Date

August 12 2020

End Date

March 5 2021

Last Update

July 13 2021

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Sleep Data

San Diego, California, United States, 92123

2

ResMed BELLA VISTA

Sydney, New South Wales, Australia, 2153